Ascendis Pharma A/S (NASDAQ:ASND) EVP Sells 20,000 Shares of Stock

Ascendis Pharma A/S logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Ascendis Pharma EVP Anni Lotte Kirstine Pedersen sold 20,000 shares for about $5.28 million at an average price of $263.89, reducing her stake by 50.68% to 19,460 shares.
  • Shares fell 0.3% to $270.33 in Wednesday midday trading, below the 52-week high of $282.15.
  • Analysts maintain a “Moderate Buy” consensus, with an average price target of $312.67; 19 analysts rate the stock Buy and two rate it Hold.
  • MarketBeat previews the top five stocks to own by December 1st.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) EVP Anni Lotte Kirstine Pedersen sold 20,000 shares of the stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $263.89, for a total value of $5,277,800.00. Following the completion of the sale, the executive vice president owned 19,460 shares of the company's stock, valued at approximately $5,135,299.40. This represents a 50.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Ascendis Pharma A/S Stock Down 0.3%

Shares of ASND traded down $0.86 during midday trading on Wednesday, reaching $270.33. 568,089 shares of the company were exchanged, compared to its average volume of 703,360. Ascendis Pharma A/S has a 1-year low of $188.08 and a 1-year high of $282.15. The stock has a 50-day moving average price of $242.71 and a 200-day moving average price of $240.31. The company has a current ratio of 2.89, a quick ratio of 2.29 and a debt-to-equity ratio of 0.25. The company has a market cap of $16.86 billion, a price-to-earnings ratio of 17.67 and a beta of 0.40.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds have recently made changes to their positions in ASND. Avior Wealth Management LLC bought a new stake in Ascendis Pharma A/S during the third quarter valued at $1,193,000. Kornitzer Capital Management Inc. KS bought a new position in shares of Ascendis Pharma A/S in the 3rd quarter worth about $3,778,000. Frazier Life Sciences Management L.P. lifted its position in shares of Ascendis Pharma A/S by 68.9% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 225,155 shares of the biotechnology company's stock worth $60,053,000 after buying an additional 91,822 shares during the last quarter. Orbimed Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 5.8% in the 1st quarter. Orbimed Advisors LLC now owns 181,977 shares of the biotechnology company's stock worth $41,624,000 after buying an additional 10,000 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Ascendis Pharma A/S by 1,105.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 17,305 shares of the biotechnology company's stock valued at $3,943,000 after buying an additional 15,870 shares during the period.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Oppenheimer upped their target price on shares of Ascendis Pharma A/S from $304.00 to $312.00 and gave the company an "outperform" rating in a research note on Tuesday, September 1st. Wall Street Zen raised shares of Ascendis Pharma A/S from a "hold" rating to a "buy" rating in a research note on Sunday, November 8th. HC Wainwright cut their price objective on shares of Ascendis Pharma A/S from $344.00 to $335.00 and set a "buy" rating on the stock in a report on Friday, November 13th. Raymond James Financial reissued an "outperform" rating on shares of Ascendis Pharma A/S in a research report on Friday, November 13th. Finally, Canaccord Genuity Group upped their price objective on shares of Ascendis Pharma A/S from $268.00 to $274.00 and gave the company a "hold" rating in a research report on Friday, November 13th. Nineteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $312.67.

Read Our Latest Stock Analysis on ASND

Ascendis Pharma A/S Company Profile

(Get Free Report)

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Ascendis Pharma A/S Right Now?

Before you consider Ascendis Pharma A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.

While Ascendis Pharma A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines